An overview of the evidence, patient selection, and cost.
Recent research suggests that GLP-1 medications — originally developed for type 2 diabetes and obesity — can also help some people reduce their alcohol use. I offer these medications as part of individualized treatment for select patients with alcohol use disorder. This page describes what the evidence shows, who is likely to benefit, the current off-label status, and the practical realities around cost and insurance.
Three randomized controlled trials have tested GLP-1 medications in alcohol use disorder to date. The most recent, published in The Lancet in 2026, gave full-dose semaglutide (Wegovy) to 108 adults with alcohol use disorder and obesity. Over six months, patients on semaglutide drank heavily on significantly fewer days than those on placebo — a meaningful reduction, on par with existing FDA-approved medications for alcohol use disorder. A 2025 trial in JAMA Psychiatry found that even nine weeks of a lower semaglutide dose reduced craving and how much participants drank on the days they did drink.
Beyond the trials, large observational studies — including a nationwide Swedish registry study of over 227,000 people with alcohol use disorder — have consistently found lower rates of alcohol-related hospitalization among people taking semaglutide.
The pattern across studies is consistent: GLP-1 medications appear to reduce craving and the intensity of drinking, rather than producing full abstinence. The strongest effects have been observed in patients who also have obesity or type 2 diabetes. A Phase 3 trial in U.S. Veterans is currently underway, with results expected in 2028.
GLP-1 medications are also being studied for cocaine use disorder and methamphetamine use disorder, but results are not yet available. For those conditions, this remains an area of active research rather than established treatment.
GLP-1 receptors are found both in the gut (where they regulate appetite and glucose) and in the brain's reward circuits (where they appear to modulate the dopamine response to alcohol and other rewarding stimuli). Unlike disulfiram, GLP-1 medications don't produce an aversive reaction to alcohol; they appear to quiet craving and the reinforcing pull of drinking. Weight loss and metabolic improvements often accompany their use.
GLP-1 medications are most appropriate for adults with alcohol use disorder who also meet criteria for a labeled indication — this is where both the strongest evidence and the clearest path to insurance coverage overlap:
For patients with alcohol use disorder alone — without one of these conditions — I consider GLP-1 medications case by case, with careful discussion of the off-label status and the more limited evidence in normal-weight adults.
Off-label prescribing means using an FDA-approved medication for a condition other than one it was formally approved for. It is legal and common in medicine when supported by evidence — most psychiatric medications are used off-label for at least some patients. GLP-1 medications are FDA-approved for type 2 diabetes, obesity, and (for tirzepatide / Zepbound) severe sleep apnea. Use for alcohol use disorder is off-label. I discuss this explicitly with every patient before we decide to start.
Costs depend on whether the patient qualifies for insurance coverage through a labeled indication (type 2 diabetes, obesity meeting BMI thresholds, or severe obstructive sleep apnea).
For patients considering a GLP-1 medication for alcohol use disorder, the initial visit is the same as any other addiction evaluation: your drinking history, other substance use, mental health, medical background, and what you'd like to change. If a GLP-1 medication is a reasonable option, we talk through the evidence, the off-label status, the likely cost, and how it would fit with the rest of your plan — behavioral care and, where appropriate, FDA-approved medications for alcohol use disorder (naltrexone, acamprosate). Ongoing medication management includes routine monitoring of dose titration, gastrointestinal side effects, and metabolic parameters.
In-person visits at my Cambridge office are available on Fridays only; all other visits are by telehealth.
FDA-approved medications for alcohol use disorder — naltrexone, acamprosate, and disulfiram — remain the first-line pharmacologic options for most patients. GLP-1 medications are an evidence-supported additional option for a specific subset of patients, particularly those with co-occurring metabolic conditions. The evidence is evolving, and I try to keep patients informed about what current research does and does not show.